Parenteral Drug Association Announces its 2020 – 2026 Strategic Plan 7 April, 2020

Bethesda, Md. – The Parenteral Drug Association, Inc. (PDA) today announced the availability of its 2020 – 2026 Strategic Plan, which was developed to assist PDA in achieving its vision to be the premier global leader in advancing bio/pharmaceutical manufacturing, science, technology, and regulation to enable members to better serve patients. The plan was developed by PDA’s Strategic Planning Committee at the direction of the PDA Board of Directors.

“A new element of the 2020 – 2026 Strategic Plan compared with previous plans is it aligns across all PDA groups,” said Richard Johnson, PDA President/CEO. “All stakeholders, including the Board of Directors, advisory volunteers, and staff, will be expected to work to achieve the objectives in the plan.”

The drivers of the 2020 – 2026 Strategic Plan are to:

• Differentiate PDA from other organization to show value to and attract new members
• Develop members and volunteer pipeline
• Promote thinking globally and acting regionally
• Sustain PDA’s growth

For more details, including a video explaining the 2020 – 2026 Strategic Plan, got to: https://www.pda.org/about-pda/strategic-plan.